Compare Becton Dickinson and Co (BDX) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Kyndryl Holdings Inc — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Kyndryl Holdings Inc trades at $11.72 (market cap $2.56B). The key difference: Becton Dickinson and Co is far larger — about 16.2× Kyndryl Holdings Inc's market cap, and Becton Dickinson and Co pays a 2.79% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals.
| BDX | KD | |
|---|---|---|
Market Cap | $41.51B | $2.56B |
Sector | Health | Technology |
52-Week High | $185.39 | $39.47 |
52-Week Low | $135.49 | $10.59 |
Enterprise Value | $57.97B | $4.89B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Kyndryl Holdings (KD) trades at $12.32, up 2.92% with a bullish technical signal. The company shows improving fundamentals with 2025 net income turning positive at $252M after years of losses, though recent quarterly earnings missed expectations. Valuation remains attractive with P/E of 14.49 and EV/EBITDA of 3.19. Recent partnerships with Microsoft and AWS for AI solutions highlight strategic positioning.
Outlook remains cautiously optimistic with analyst consensus target of $14.33 offering 16% upside. Key risks include ongoing earnings volatility, internal control investigations, and high debt levels. The transformation toward higher-margin services provides growth potential, but execution risks and competitive pressures require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
